Our vision is to set up a sustainable and flexible platform for molecular imaging of immune cell dynamics using novel tracer strategies. New immunotracers will enable smart monitoring of immunotherapies and widespread usage of a personalised medicine approach.
Immunotherapies are revolutionising the treatment of many cancers and inflammatory diseases. However, immunotherapies are not always successful due to specific disease features in each patient and adaption of the immune system and the tumor during treatment. Therefore, there is an urgent clinical need to assess the immune status of individual patient and to regularly monitor the response to immunotherapy.
Immune-Image will develop methods to visualize and study the immune cells involved before, during, and after immunotherapy, allowing selection of the right treatment for the right patient at the right time.
Immune-Image brings together 22 key stakeholders from across 9 countries. This consortium comprises 10 academic institutions, 4 SMEs, 1 patient organization and 7 pharmaceutical companies.
On January 27-28, 2020 the Immune-Image consortium got together in Amsterdam to officially kick-off the project! The kick-off meeting was the first time that all consortium partners met to share knowledge, discuss the workplan for upcoming years and align partner...
Innovative Medicines Initiative awards 30 Million Euro grant supporting research into novel tracer strategies for clinical imaging of immune cell dynamics The Innovative Medicines Initiative Joint Undertaking (IMI2 JU) project ‘Immune-Image’ has been approved for...